IBDEI3DE ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,56657,2)
 ;;=^5002649
 ;;^UTILITY(U,$J,358.3,56658,0)
 ;;=E11.51^^261^2831^91
 ;;^UTILITY(U,$J,358.3,56658,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56658,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,56658,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,56658,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,56659,0)
 ;;=E11.52^^261^2831^92
 ;;^UTILITY(U,$J,358.3,56659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56659,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,56659,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,56659,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,56660,0)
 ;;=E11.610^^261^2831^89
 ;;^UTILITY(U,$J,358.3,56660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56660,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,56660,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,56660,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,56661,0)
 ;;=E11.620^^261^2831^87
 ;;^UTILITY(U,$J,358.3,56661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56661,1,3,0)
 ;;=3^DM Type 2 w/ DM Dermatitis
 ;;^UTILITY(U,$J,358.3,56661,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,56661,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,56662,0)
 ;;=E11.621^^261^2831^94
 ;;^UTILITY(U,$J,358.3,56662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56662,1,3,0)
 ;;=3^DM Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,56662,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,56662,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,56663,0)
 ;;=E11.622^^261^2831^99
 ;;^UTILITY(U,$J,358.3,56663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56663,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,56663,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,56663,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,56664,0)
 ;;=E11.630^^261^2831^98
 ;;^UTILITY(U,$J,358.3,56664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56664,1,3,0)
 ;;=3^DM Type 2 w/ Periodontal Disease
 ;;^UTILITY(U,$J,358.3,56664,1,4,0)
 ;;=4^E11.630
 ;;^UTILITY(U,$J,358.3,56664,2)
 ;;=^5002659
 ;;^UTILITY(U,$J,358.3,56665,0)
 ;;=E11.641^^261^2831^96
 ;;^UTILITY(U,$J,358.3,56665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56665,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,56665,1,4,0)
 ;;=4^E11.641
 ;;^UTILITY(U,$J,358.3,56665,2)
 ;;=^5002661
 ;;^UTILITY(U,$J,358.3,56666,0)
 ;;=E11.649^^261^2831^97
 ;;^UTILITY(U,$J,358.3,56666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56666,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,56666,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,56666,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,56667,0)
 ;;=E11.65^^261^2831^95
 ;;^UTILITY(U,$J,358.3,56667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56667,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,56667,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,56667,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,56668,0)
 ;;=G56.41^^261^2831^59
 ;;^UTILITY(U,$J,358.3,56668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56668,1,3,0)
 ;;=3^Causalgia Rt Upper Limb
 ;;^UTILITY(U,$J,358.3,56668,1,4,0)
 ;;=4^G56.41
 ;;^UTILITY(U,$J,358.3,56668,2)
 ;;=^5004030
 ;;^UTILITY(U,$J,358.3,56669,0)
 ;;=G56.42^^261^2831^58
 ;;^UTILITY(U,$J,358.3,56669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56669,1,3,0)
 ;;=3^Causalgia Lt Upper Limb
 ;;^UTILITY(U,$J,358.3,56669,1,4,0)
 ;;=4^G56.42
 ;;^UTILITY(U,$J,358.3,56669,2)
 ;;=^5004031
 ;;^UTILITY(U,$J,358.3,56670,0)
 ;;=I65.21^^261^2831^124
 ;;^UTILITY(U,$J,358.3,56670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56670,1,3,0)
 ;;=3^Occlusion & Stenosis Rt Carotid Artery
